CureVac N.V. (CVAC)
| Bid | 3.39 |
| Market Cap | 766.66M |
| Revenue (ttm) | 535.18M |
| Net Income (ttm) | 162.19M |
| EPS (ttm) | 0.82 |
| PE Ratio (ttm) | 4.15 |
| Forward PE | -12.22 |
| Analyst | Buy |
| Ask | 3.5 |
| Volume | 353,145 |
| Avg. Volume (20D) | 634,932 |
| Open | 3.58 |
| Previous Close | 3.55 |
| Day's Range | 3.38 - 3.58 |
| 52-Week Range | 2.37 - 5.28 |
| Beta | 2.48 |
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 cli...
Analyst Forecast
According to 2 analyst ratings, the average rating for CVAC stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 311.16% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · accessnewswire.com
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top InnovatorsCureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of t...